New use for an old drug: Inhibiting ABCG2 with sorafenib

Molecular Cancer Therapeutics

Volumn 11, Issue 8, 2012, Pages 1693-1702

  Wei, Yinxiang ^a,c   Ma, Yuanfang ^c   Zhao, Qing ^a,d   Ren, Zhiguang ^a,c   Li, Yan ^a   Hou, Tingjun ^b   Peng, Hui ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b SOOCHOW UNIVERSITY   (China)

^c HENAN UNIVERSITY   (China)

^d NANKAI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4,6,7,12,12A OCTAHYDRO 6 ISOBUTYL 9 METHOXY 1,4 DIOXOPYRAZINO[1',2':1,6]PYRIDO[3,4 B]INDOLE 3 PROPANOIC ACID TERT BUTYL ESTER; BREAST CANCER RESISTANCE PROTEIN; MITOXANTRONE; SORAFENIB; VERAPAMIL;

ARTICLE; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG USE; FLUORESCENCE ACTIVATED CELL SORTING; GENE TARGETING; HUMAN; HUMAN TISSUE; LYSOSOME; MULTIDRUG RESISTANCE; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BENZENESULFONATES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SPACE; MITOXANTRONE; MOLECULAR CONFORMATION; NEOPLASM PROTEINS; PROTEIN BINDING; PYRIDINES; SIGNAL TRANSDUCTION;

EID: 84864869645     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0215     Document Type: Article

References (30)

1. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34.
2. Zhang JT. Biochemistry and pharmacology of the human multidrug resistance gene product, ABCG2. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2007;32:531-41.
3. Robey RW, Ierano C, Zhan Z, Bates SE. The challenge of exploiting ABCG2 in the clinic. Curr Pharm Biotechnol 2011;12:595- 608.
4. Xu J, Peng H, Zhang JT. Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy. Curr Med Chem 2007;14:689-701. (Pubitemid 46477721)
5. He M, Wei MJ. Reversing multidrug resistance by tyrosine kinase inhibitors. Chin J Cancer 2012;31:126-33.
6. Mi YJ, Liang YJ, Huang HB, Zhao HY, Wu CP, Wang F, et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res 2010;70:7981-91.
7. Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, et al. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett 2009;279:74-83.
8. Dai C, Tiwari AK,WuCP, Su X, Wang SR, Liu D, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 2008;68:7905.
9. Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamilyGmember 2-mediated drug resistance. Cancer Res 2007;67:11012- 20.
10. Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, et al. Ge fitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 2005;65: 1541 - 6.
11. Liu W, Baer MR, Bowman MJ, Pera P, Zheng X, Morgan J, et al. The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res 2007; 13:2463-70. (Pubitemid 46698598)
12. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr., Chen X, et al. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol 2009;78:153- 61.
13. Zheng L, Wang F, Li Y, Zhang X, Chen L, Liang Y, et al. Vandetanib (Zactima, ZD6474) antagonizes ABCC1-and ABCG2-mediated multidrug resistance by inhibition of their transport function. PLoS One 2009;4:e5172.
14. Wang XK, Fu LW. Interaction of tyrosine kinase inhibitors with the MDR-related ABC transporter proteins. Curr Drug Metab 2010;11: 618-28.
15. Peng H, Dong Z, Qi J, Yang Y, Liu Y, Li Z, et al.A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy. PLoS One 2009;4:e5676.
16. Peng H, Qi J, Dong Z, Zhang JT. Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells. PLoS One 2010;5:e15276.
17. Yang CZ, Luan FJ, Xiong DS, Liu BR, Xu YF, Gu KS. Multidrug resistance in leukemic cell line K562/A02 induced by doxorubicin. Zhongguo Yao Li Xue Bao 1995;16:333-7.
18. Xu J, Peng H, Chen Q, Liu Y, Dong Z, Zhang JT. Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity. Cancer Res 2007;67:4373-81. (Pubitemid 46815086)
19. Yang Y, Chen Q, Zhang JT. Structural and functional consequences of mutating cysteine residues in the amino terminus of human multidrug resistance-associated protein 1. J Biol Chem 2002;277:44268-77. (Pubitemid 36157860)
20. Xu J, Liu Y, Yang Y, Bates S, Zhang JT. Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J Biol Chem 2004;279:19781-9. (Pubitemid 38623417)
21. Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res 2002;62:5035-40. (Pubitemid 34984431)
22. Henrich CJ, Robey RW, Bokesch HR, Bates SE, Shukla S, Ambudkar SV, et al. New inhibitors of ABCG2 identified by high-throughput screening. Mol Cancer Ther 2007;6:3271-8.
23. Lacerda L, Pusztai L, Woodward WA. The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches. Drug Resist Updat 2010;13:99-108.
24. Broxterman HJ, Gotink KJ, Verheul HM. Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat 2009;12:114-26.
25. Agarwal S, Sane R, Ohlfest JR, Elmquist WF. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther 2011;336:223-33.
26. Lagas JS, van Waterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther 2010;9:319-26.
27. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009;15: 6062-9.
28. Poller B, Wagenaar E, Tang SC, Schinkel AH. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm 2011;8:571-82.
29. Hegedus C, Ozvegy-Laczka C, Szakacs G, Sarkadi B. Interaction of ABC multidrug transporters with anticancer protein kinase inhibitors: substrates and/or inhibitors? Curr Cancer Drug Targets 2009;9: 252-72.
30. Blanchet B, Billemont B, Cramard J, Benichou AS, Chhun S, Harcouet L, et al. Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal 2009;49:1109-14.